Related Experiment Videos
Biological and clinical importance of the p53 tumor suppressor gene
1The Johns Hopkins Oncology Center, Baltimore, MD 21231, USA.
Abstract:
The p53 tumor suppressor gene controls cellular growth after DNA damage through mechanisms involving growth arrest and apoptosis. Mutations that inactivate p53 occur commonly in virtually all human malignancies and can be detected by sequencing of the p53 gene, immunohistochemical staining of tumor tissue with anti-p53 antibodies, single-strand conformation polymorphisms, or other biological assays. Identification of p53 mutation in the germ line is diagnostic of the cancer-prone Li-Fraumeni syndrome. Alterations of the p53 gene result in defective cellular responses after DNA damage and predispose cells to dysregulated growth, tumor formation and progression, and potential resistance (of tumor cells) to certain chemotherapeutic agents or ionizing radiation. A variety of tumors involving mutant p53 have a worse prognosis than tumors of the same type containing no p53 mutations. New diagnostic and therapeutic strategies are evolving as the p53 pathways of cell-cycle arrest and apoptosis become elucidated.
Insights
Mutations in the p53 tumor suppressor gene are common in human cancers, leading to uncontrolled cell growth and poor prognosis. Detecting p53 alterations aids in diagnosing Li-Fraumeni syndrome and guides cancer treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The p53 tumor suppressor gene plays a critical role in regulating cellular responses to DNA damage, including growth arrest and apoptosis.
- Inactivating mutations of the p53 gene are prevalent in a wide range of human malignancies.
Purpose of the Study:
- To summarize the significance of p53 gene mutations in cancer development and progression.
- To highlight the diagnostic and therapeutic implications of p53 alterations.
Main Methods:
- Detection of p53 gene mutations through DNA sequencing.
- Immunohistochemical staining of tumor tissues using anti-p53 antibodies.
- Analysis of biological assays such as single-strand conformation polymorphisms.
Main Results:
- Germline p53 mutations are indicative of the Li-Fraumeni syndrome, a cancer predisposition disorder.
- p53 alterations lead to impaired cellular responses to DNA damage, promoting tumor formation and progression.
- Tumors with mutant p53 often exhibit a poorer prognosis compared to those with wild-type p53.
- Mutant p53 can confer resistance to certain chemotherapies and radiation.
Conclusions:
- Understanding p53 pathways is crucial for developing novel diagnostic and therapeutic strategies in oncology.
- Targeting p53 dysfunction holds promise for improving cancer treatment outcomes.